Ferroptosis is a distinct form of regulated cell death characterized by iron-dependent lipid peroxidation accumulation. Unlike [apoptosis](/mechanisms/apoptosis-neurodegeneration) or necrosis, ferroptosis is driven by the failure of the glutathione antioxidant system, leading to membrane lipid peroxidation and cell death. This pathway has emerged as a critical mechanism in neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS). [@stockwell2020]
The concept of ferroptosis was first formalized in 2012, building on earlier observations that certain cancer cell lines underwent a unique form of non-apoptotic cell death in response to erastin, a small molecule inhibitor of the cystine/glutamate antiporter system Xc-. Since then, research has rapidly expanded to reveal the importance of ferroptosis in developmental biology, cancer biology, and particularly in neurodegenerative diseases. The recognition that ferroptosis represents a fundamentally different cell death pathway from apoptosis, necrosis, or autophagy has profound implications for understanding disease mechanisms and developing therapeutic interventions. [@weiland2019]
Ferroptosis is a distinct form of regulated cell death characterized by iron-dependent lipid peroxidation accumulation. Unlike [apoptosis](/mechanisms/apoptosis-neurodegeneration) or necrosis, ferroptosis is driven by the failure of the glutathione antioxidant system, leading to membrane lipid peroxidation and cell death. This pathway has emerged as a critical mechanism in neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS). [@stockwell2020]
The concept of ferroptosis was first formalized in 2012, building on earlier observations that certain cancer cell lines underwent a unique form of non-apoptotic cell death in response to erastin, a small molecule inhibitor of the cystine/glutamate antiporter system Xc-. Since then, research has rapidly expanded to reveal the importance of ferroptosis in developmental biology, cancer biology, and particularly in neurodegenerative diseases. The recognition that ferroptosis represents a fundamentally different cell death pathway from apoptosis, necrosis, or autophagy has profound implications for understanding disease mechanisms and developing therapeutic interventions. [@weiland2019]
The ferroptosis cascade involves a coordinated interplay between iron metabolism, lipid peroxidation, and the glutathione antioxidant system. Understanding these core components is essential for appreciating how dysregulation leads to neuronal death in neurodegenerative diseases. [@masaldan2019]
| Component | Function | Disease Relevance |
|-----------|----------|-------------------|
| GPX4 (Glutathione Peroxidase 4) | Reduces lipid peroxides to alcohols | Key inhibitor of ferroptosis |
| GSH (Glutathione) | Antioxidant cofactor for GPX4 | Depleted in AD/PD brains |
| System Xc- | Cystine/glutamate antiporter | Target of erastin |
| Iron (Fe2+) | Fenton reaction catalyst | Accumulates in neurodegeneration |
| Lipoxygenases | Oxidize polyunsaturated fatty acids | Active in neuroinflammation |
Glutathione peroxidase 4 (GPX4) is the central enzyme that prevents ferroptosis by reducing lipid peroxides to their corresponding alcohols. Unlike other GPX isoforms, GPX4 can directly reduce phospholipid hydroperoxides within cellular membranes, making it uniquely positioned to prevent ferroptotic cell death. The enzyme requires glutathione (GSH) as its cofactor, and the availability of both GPX4 and GSH determines whether cells can survive lipid peroxidation stress. In neurons, GPX4 expression is particularly important due to the high lipid content of neuronal membranes and the continuous oxidative stress that these cells face. [@dovan2016]
The system Xc- (also known as SLC7A11) is a heterodimeric amino acid antiporter that imports cystine in exchange for exporting glutamate. This system is the primary source of intracellular cysteine, which is then converted to GSH. Inhibition of system Xc- by erastin or related compounds depletes intracellular GSH, leading to GPX4 inactivation and subsequent ferroptosis. In neurodegenerative diseases, system Xc- function may be compromised through multiple mechanisms, including oxidative modification, transcriptional downregulation, and impaired cystine uptake. [@conrad2019]
The Fenton reaction is the iron-catalyzed conversion of hydrogen peroxide to hydroxyl radical, a highly reactive oxygen species that initiates lipid peroxidation. In ferroptosis, the iron requirement is absolute—cells cannot undergo ferroptosis in the absence of iron, and iron chelators potently inhibit the process. The labile iron pool within cells must be carefully regulated, and disruption of this balance contributes to neurodegeneration through multiple mechanisms beyond ferroptosis. [@angeli2019]
Neurons are particularly vulnerable to iron dysregulation due to their high metabolic demands and limited regenerative capacity. The substantia nigra pars compacta in PD and the hippocampus in AD show marked iron accumulation, and this iron is redox-active, capable of generating hydroxyl radicals through the Fenton reaction. Iron homeostasis in the brain involves multiple proteins including ferritin (iron storage), transferrin (iron transport), and ferroportin (iron export), and dysregulation of any of these components can contribute to ferroptotic vulnerability. [@devos2019]
Lipoxygenases (LOXs) are a family of enzymes that catalyze the oxidation of polyunsaturated fatty acids (PUFAs). In the context of ferroptosis, LOX-mediated peroxidation of membrane phospholipids containing PUFAs is a key driver of membrane damage. The identification of specific LOX isoforms involved in ferroptosis has revealed potential therapeutic targets, and pharmacological inhibition of LOXs can prevent ferroptosis in various models. [@wenzel2017]
The lipid composition of neuronal membranes is particularly relevant to ferroptosis susceptibility. Neurons contain high levels of long-chain PUFAs, particularly arachidonic acid and docosahexaenoic acid, which are excellent substrates for lipid peroxidation. This membrane composition, while essential for proper neuronal function and synaptic plasticity, creates an inherent vulnerability to ferroptotic death when antioxidant defenses are compromised. Additionally, the subcellular localization of PUFAs—such as in synaptic membranes—may explain the particular susceptibility of synapses to ferroptotic damage in neurodegenerative diseases. [@maher2018]
[Alzheimer's disease](/diseases/alzheimers-disease) represents perhaps the most extensively studied context for ferroptosis in neurodegeneration. Multiple converging lines of evidence support a role for ferroptotic cell death in AD pathogenesis. First, iron accumulation in the [hippocampus](/brain-regions/hippocampus) and [basal ganglia](/brain-regions/basal-ganglia) is a well-documented feature of AD brains, with iron levels correlating with disease severity. Second, glutathione levels are reduced in AD brains, compromising the GPX4 system. Third, GPX4 expression is decreased in AD brains, and mouse models lacking GPX4 show accelerated age-related neurodegeneration. [@liu2024]
The relationship between ferroptosis and the established hallmarks of AD is complex and bidirectional. [Amyloid-beta](/proteins/amyloid-beta-protein) aggregation promotes iron accumulation through multiple mechanisms, including disruption of iron export and increased ferritin degradation. Similarly, [tau](/proteins/tau) pathology interferes with iron regulatory proteins, further exacerbating iron dysregulation. This creates a feedforward loop where amyloid and tau pathology drive ferroptosis susceptibility, and ferroptotic cell death contributes to further amyloid and tau propagation. Iron-induced lipid peroxidation also directly promotes amyloid-beta aggregation, linking these processes at a mechanistic level. [@zhang2024]
In [Parkinson's disease](/diseases/parkinsons-disease), ferroptosis has emerged as a particularly relevant cell death pathway. The characteristic iron accumulation in the [substantia nigra pars compacta](/brain-regions/substantia-nigra) has long been recognized, and recent research has confirmed that this iron is redox-active and capable of driving lipid peroxidation. Additionally, dopaminergic neurons are particularly vulnerable to ferroptosis due to their high dopamine content, which can undergo auto-oxidation to form quinones that promote oxidative stress. [@bai2023]
Genetic forms of PD provide further evidence for ferroptosis involvement. Mutations in [PINK1](/genes/pink1), [Parkin](/genes/parkin), and [GBA](/genes/gba) all affect pathways that intersect with ferroptosis regulation. PINK1 and Parkin are involved in mitophagy, and impaired mitophagy leads to accumulation of damaged mitochondria that generate increased ROS. GBA mutations affect lipid metabolism and lysosomal function, which impacts both iron homeostasis and the glutathione system. These genetic insights suggest that multiple pathways converge on ferroptosis vulnerability in PD. [@dovan2016]
In [ALS](/diseases/amyotrophic-lateral-sclerosis), ferroptosis markers are elevated in patient tissues and models. GPX4 expression is reduced in [motor neurons](/cell-types/motor-neurons) from ALS patients, and lipid peroxidation products accumulate. Mutations in [SOD1](/genes/sod1), which cause familial ALS, lead to increased oxidative stress and promote ferroptosis susceptibility. Additionally, the aggregation of TDP-43, the protein that accumulates in most ALS cases, is linked to impaired ferroptosis regulation. Ferroptosis may also contribute to non-cell autonomous damage in ALS through microglial ferroptosis, which could promote neuroinflammation. [@wang2024]
Recent research has identified alternative pathways that can compensate for or operate independently of GPX4. These discoveries have important implications for therapeutic targeting, as they suggest that single-target approaches may be insufficient. The FSP1-CoQ10-NAD(P)H system provides GPX4-independent ferroptosis inhibition through ubiquinol regeneration. The GCH1-BH4 axis also promotes ferroptosis resistance through tetrahydrobiopterin synthesis. These alternative pathways may be particularly relevant in specific neuronal populations or disease contexts, and targeting them could provide additional therapeutic benefit. [@yang2024]
Multiple strategies for ferroptosis inhibition are being developed for neurodegenerative diseases. The most direct approach involves compounds that directly inhibit lipid peroxidation, such as ferrostatin-1 and liproxstatin-1. These compounds are potent ferroptosis inhibitors in vitro but have limited brain penetration. Newer generations of ferroptosis inhibitors with improved blood-brain barrier penetration are in development and show promise in animal models of PD and AD. [@chen2024]
| Compound | Mechanism | Development Stage |
|----------|-----------|-------------------|
| Ferrostatin-1 | Lipid ROS scavenger | Preclinical |
| Liproxstatin-1 | Inhibits lipid peroxidation | Preclinical |
| Vitamin E | Antioxidant, blocks lipid peroxidation | Clinical trials |
| Deferoxamine | Iron chelator | Clinical trials |
| RSL3 derivatives | GPX4 activators | Preclinical |
Iron chelation represents a mechanistically straightforward approach to preventing ferroptosis. Deferoxamine (DFO) has been tested in PD and AD clinical trials with mixed results. The challenge with iron chelation is achieving adequate brain penetration while avoiding systemic side effects. Alternative chelators including deferasirox and clioquinol are being evaluated for neurodegenerative disease applications. Additionally, compounds that modulate iron metabolism without direct chelation—such as targeting ferroportin—are under investigation. [@devos2019]
Strategies to boost the glutathione system include providing GSH precursors, upregulating GSH synthesis through Nrf2 activation, and directly enhancing GPX4 expression or activity. Nrf2 activators such as sulforaphane and bardoxolone methyl are in clinical trials for various indications and may have relevance for ferroptosis in neurodegeneration. Additionally, compounds that stabilize GPX4 or prevent its degradation could provide therapeutic benefit. [@song2020]
Given the role of lipoxygenases in generating lipid peroxides, LOX inhibitors represent another therapeutic approach. Several LOX inhibitors are approved for other indications (e.g., zileuton for asthma) and could be repurposed for neurodegenerative diseases. However, the involvement of multiple LOX isoforms and their diverse biological functions presents challenges for therapeutic targeting.
The relationship between ferroptosis and [neuroinflammation](/mechanisms/neuroinflammation) is bidirectional. Ferroptotic cells release damage-associated molecular patterns (DAMPs) that activate [microglia](/cell-types/microglia) and promote inflammatory responses. Conversely, activated microglia can undergo ferroptosis, releasing additional inflammatory mediators and creating a feedforward loop of neuroinflammation and cell death. This intersection between ferroptosis and neuroinflammation suggests that combination therapies targeting both processes may be particularly effective. [@wang2024]
Microglial ferroptosis has emerged as an important contributor to neurodegenerative disease progression. In AD and PD, microglia in affected brain regions show markers of ferroptosis, including lipid peroxidation and iron accumulation. This microglial ferroptosis may be triggered by either cell-autonomous mechanisms (e.g., from phagocytosed material containing iron or lipid peroxides) or non-cell-autonomous signals from neurons undergoing ferroptosis. The inflammatory consequences of microglial ferroptosis include increased cytokine release, complement activation, and synaptic elimination—all features of neurodegenerative disease pathology.
The development of ferroptosis biomarkers is essential for clinical translation. Current approaches include measuring lipid peroxidation products (e.g., 4-hydroxynonenal, malondialdehyde), iron metabolism markers (ferritin, transferrin), and GPX4 activity. CSF biomarkers for ferroptosis in neurodegenerative diseases are under development, though no validated clinical biomarker exists yet. Imaging probes for iron and lipid peroxidation are also being developed for PET and MRI applications.
Recent advances in ferroptosis research have significantly advanced our understanding of its role in neurodegenerative diseases:
Ferroptosis represents a fundamental cell death pathway with clear relevance to neurodegenerative diseases. The convergence of iron accumulation, glutathione depletion, and lipid peroxidation in AD, PD, and ALS provides compelling evidence for ferroptosis involvement in these conditions. Therapeutic targeting of ferroptosis offers a novel approach that addresses upstream mechanisms common to multiple neurodegenerative diseases. However, significant challenges remain, including the development of brain-penetrant inhibitors, identification of patient subgroups who may benefit most from ferroptosis-targeting therapies, and understanding the relationship between ferroptosis and other cell death pathways in neurodegeneration.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
The following diagram shows the key molecular relationships involving Ferroptosis Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis: